ID Biomedical Gets U.S. OK to Test Flu Drug
- Share via
ID Biomedical Corp. said it had been cleared by U.S. regulators to start tests of its flu drug, paving the way for the small-scale company to become a big player in the U.S. flu vaccine market.
Vancouver, Canada-based ID Biomedical said it intended to ship Fluviral to the United States and would start enrolling people for the trial before the end of January.
The company also said it was in talks with the Food and Drug Administration about a strategy for Fluviral’s entry into the United States.
On Nasdaq, ID Biomedical shares rose 97 cents to $15.17.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
